Dietary Fermentable Fibers Attenuate Chronic Kidney Disease in Mice by Protecting the Intestinal Barrier

2018/01/31 by Tran Van Hung, Takuya Suzuki · 26 citations
Neuroscience · Biochemistry, Genetics and Molecular Biology · Medicine · #Barrier Structure and Function Studies #Gut microbiota and health #Chronic Kidney Disease and Diabetes

paper · pdf · doi:10.1093/jn/nxy008

Citations

• AIN-93 Purified Diets for Laboratory Rodents: Final Report of the American Institute of Nutrition Ad Hoc Writing Committee on the Reformulation of the AIN-76A Rodent Diet

Cited by

• Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis
• Dietary Components That May Influence the Disturbed Gut Microbiota in Chronic Kidney Disease. [europepmc]
• Role for diet in normal gut barrier function: developing guidance within the framework of food-labeling regulations. [europepmc]
• Partially Hydrolyzed Guar Gum Attenuates d-Galactose-Induced Oxidative Stress and Restores Gut Microbiota in Rats. [europepmc]
• Exacerbation of Chikungunya Virus Rheumatic Immunopathology by a High Fiber Diet and Butyrate. [europepmc]
• The Kidney-Gut-Muscle Axis in End-Stage Renal Disease is Similarly Represented in Older Adults. [europepmc]
• Renoprotective effects of paramylon, a β-1,3-D-Glucan isolated from Euglena gracilis Z in a rodent model of chronic kidney disease. [europepmc]
• Citrus limon Peel Powder Reduces Intestinal Barrier Defects and Inflammation in a Colitic Murine Experimental Model. [europepmc]
• The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. [europepmc]
• Gut Microbiota Dysbiosis Is a Crucial Player for the Poor Outcomes for COVID-19 in Elderly, Diabetic and Hypertensive Patients. [europepmc]
• Role of the gut microbiome in chronic diseases: a narrative review. [europepmc]
• Effects of prebiotic oligofructose-enriched inulin on gut-derived uremic toxins and disease progression in rats with adenine-induced chronic kidney disease. [europepmc]
• Present and Future Therapeutic Approaches to Barrier Dysfunction. [europepmc]
• Gut Dysbiosis and Kidney Diseases. [europepmc]
• Short-Chain Fatty Acids in Chronic Kidney Disease: Focus on Inflammation and Oxidative Stress Regulation. [europepmc]
• Respiratory and Intestinal Microbiota in Pediatric Lung Diseases-Current Evidence of the Gut-Lung Axis. [europepmc]
• Gut-Kidney Axis Investigations in Animal Models of Chronic Kidney Disease. [europepmc]
• Natural products from plants and microorganisms: Novel therapeutics for chronic kidney disease via gut microbiota regulation. [europepmc]
• Interaction between gut microbiota and sex hormones and their relation to sexual dimorphism in metabolic diseases. [europepmc]
• A novel model of adenine-induced chronic kidney disease-associated gastrointestinal dysfunction in mice: The gut-kidney axis. [europepmc]
• Effectiveness of Partially Hydrolyzed Guar Gum on Cognitive Function and Sleep Efficiency in Healthy Elderly Subjects in a Randomized, Double-Blind, Placebo-Controlled, and Parallel-Group Study. [europepmc]
• The interplay between gut microbiota, short-chain fatty acids, and implications for host health and disease. [europepmc]
• Partially hydrolyzed guar gum suppresses binge alcohol-induced liver fat accumulation via gut environment modulation in mice. [europepmc]
• The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases. [europepmc]
• Common mechanisms of Gut microbe-based strategies for the treatment of intestine-related diseases: based on multi-target interactions with the intestinal barrier. [europepmc]
• Gut Microbiota Dysbiosis and Its Impact on Type 2 Diabetes: From Pathogenesis to Therapeutic Strategies. [europepmc]